MDT

99.36

+1.42%↑

A

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

A

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

A

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

A

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

A

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

Search

Celldex Therapeutics Inc

Deschisă

SectorSănătate

25.73 -2.17

Rezumat

Modificarea prețului

24h

Curent

Minim

25.15

Maxim

26.55

Indicatori cheie

By Trading Economics

Venit

-10M

-67M

Marjă de profit

-7,753.425

Angajați

186

EBITDA

-9.8M

-73M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+112.11% upside

Dividende

By Dow Jones

Următoarele câștiguri

25 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

200M

1.7B

Deschiderea anterioară

27.9

Închiderea anterioară

25.73

Sentimentul știrilor

By Acuity

50%

50%

151 / 361 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Celldex Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 ian. 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 ian. 2026, 00:00 UTC

Câștiguri

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 ian. 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 ian. 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 ian. 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 ian. 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 ian. 2026, 22:56 UTC

Achiziții, Fuziuni, Preluări

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 ian. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 ian. 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 ian. 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 ian. 2026, 22:09 UTC

Câștiguri

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 ian. 2026, 22:08 UTC

Câștiguri

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 ian. 2026, 22:08 UTC

Câștiguri

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 ian. 2026, 21:53 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 ian. 2026, 21:53 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 ian. 2026, 21:52 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC Announces Positive Profit Alert for 2025

14 ian. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Citigroup Acting as Financial Advisor to WuXi XDC

14 ian. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 ian. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 ian. 2026, 21:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

14 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 ian. 2026, 21:49 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 ian. 2026, 21:48 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 ian. 2026, 21:48 UTC

Achiziții, Fuziuni, Preluări

WuXi XDC Makes Cash Offer for BioDlink International

14 ian. 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 ian. 2026, 20:30 UTC

Market Talk
Câștiguri

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 ian. 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 ian. 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 ian. 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 ian. 2026, 19:06 UTC

Market Talk
Câștiguri

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Comparație

Modificare preț

Celldex Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

112.11% sus

Prognoză pe 12 luni

Medie 55 USD  112.11%

Maxim 90 USD

Minim 24 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCelldex Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

9

Cumpărare

0

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

18.91 / 20.63Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

151 / 361 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat